US Drug Patent 8,017,655: Scope, Claims, Expiration, Litigation and Bimatoprost Patent Landscape

US Patent 8,017,655 covers a narrow bimatoprost ophthalmic formulation containing benzalkonium chloride and sodium chloride. Its core commercial relevance is Lumigan ophthalmic solution, a bimatoprost product marketed by Allergan, now part of AbbVie. The independent claim does not require a stated bimatoprost concentration, ophthalmic route, dropper, pH range, intraocular-pressure indication, or glaucoma indication. Those limitations appear only in dependent claims.

The patent is formulation-specific rather than molecule-wide. It does not block every bimatoprost product. A competing product may avoid literal infringement by changing one or more required formulation elements, although the doctrine of equivalents, regulatory certifications, and other patents in the Lumigan estate remain relevant.

What drug and formulation does US Patent 8,017,655 protect?

The active ingredient described in the claims is bimatoprost, although the claim uses a systematic chemical description rather than the International Nonproprietary Name. Bimatoprost is a prostamide analog used to reduce intraocular pressure in glaucoma and ocular hypertension.

Patent element	Scope under claim 1	Commercial significance
Active ingredient	Bimatoprost chemical compound	Identifies the protected drug substance
Benzalkonium chloride	Required	Preservative and formulation component
Sodium chloride	Required as a tonicity agent	Controls osmolality
Pharmaceutical composition	Required	Requires a composition, not bimatoprost alone
Ophthalmic use	Not required by claim 1, but added by claim 2	Central to Lumigan relevance
Dropper package	Added only by claim 3	Packaging-specific limitation
pH 4.5-7.5	Added only by claim 4	Narrows the formulation
Intraocular-pressure reduction	Added only by claim 5	Method-of-use limitation
Glaucoma treatment	Added only by claim 6	Method-of-use limitation

The claim language supplied for the active ingredient corresponds to bimatoprost. The commercial product Lumigan contains bimatoprost in an aqueous ophthalmic solution with benzalkonium chloride and sodium chloride. The FDA-approved Lumigan 0.01% product also contains other excipients, including phosphate buffers and purified water, but additional excipients do not ordinarily avoid a claim requiring the listed ingredients. [1]

What are the independent and dependent claims in US 8,017,655?

Claim 1 is the controlling composition claim. It requires a pharmaceutical composition comprising:

Bimatoprost;
Benzalkonium chloride; and
Sodium chloride as a tonicity agent.

The word "comprising" generally makes the claim open-ended. A product containing these three required elements may infringe even if it contains additional ingredients, unless another claim-construction issue changes the result.

Claims 2 through 4 narrow the composition:

Claim 2 requires ophthalmic application.
Claim 3 requires packaging in a dropper for ophthalmic application.
Claim 4 requires a pH between 4.5 and 7.5.

Claims 5 and 6 are method-of-use claims in functional form:

Claim 5 covers use to lower intraocular pressure.
Claim 6 covers treatment of glaucoma.

Claim hierarchy

Claim	Type	Additional limitation	Relative breadth
1	Composition	Bimatoprost, benzalkonium chloride and sodium chloride	Broadest
2	Composition/use context	Ophthalmic application	Narrower
3	Composition/package	Dropper packaging	Narrower
4	Composition	pH 4.5-7.5	Narrower
5	Method of use	Lowering intraocular pressure	Narrower
6	Method of use	Treating glaucoma	Narrower

The claim set does not state the bimatoprost concentration. That omission materially broadens claim 1 compared with a claim limited to 0.01% or 0.03% bimatoprost. It also does not expressly require sterility, a particular buffer, a particular viscosity, a specific bottle material, or a particular dosing schedule.

How broad is the scope of claim 1?

Claim 1 potentially reaches any pharmaceutical composition containing the claimed bimatoprost compound, benzalkonium chloride, and sodium chloride used as a tonicity agent. The claim does not appear limited to:

A particular bimatoprost concentration;
A specific ophthalmic dosage form;
A particular volume or fill size;
A particular bottle or dropper design;
A particular buffer system;
A particular pH;
A particular indication;
A particular preservative concentration; or
A particular commercial brand.

The principal claim-construction issues are likely to concern the meaning of "comprising," whether sodium chloride must function as a tonicity agent in the finished product, and whether the chemical nomenclature unambiguously identifies bimatoprost.

A formulation with trace sodium chloride that does not materially contribute to tonicity could present a noninfringement position. That position would depend on the intrinsic evidence, specification, prosecution history, formulation data and expert testimony. A product using another tonicity agent, such as glycerin, boric acid, mannitol or a different salt system, may avoid literal infringement if it contains no sodium chloride. That design-around may still face other formulation patents.

What formulations are protected by US 8,017,655?

The most commercially important protected formulation is a preserved aqueous bimatoprost ophthalmic solution containing benzalkonium chloride and sodium chloride. The patent can reach both branded and generic versions if their approved formulations contain all required claim 1 components.

Likely within claim 1

A product is a strong literal-infringement candidate if it contains:

Bimatoprost;
Benzalkonium chloride as preservative;
Sodium chloride as tonicity agent; and
An aqueous pharmaceutical formulation.

The product need not be labeled Lumigan. The patent claim is not limited to Allergan's trade name, bottle design or labeled concentration.

Potential design-around categories

Design-around	Claim 1 risk	Main issue
Replace sodium chloride with glycerin or mannitol	Lower literal risk	Must avoid sodium chloride functioning as tonicity agent
Use a preservative-free multidose system	Lower literal risk	No benzalkonium chloride may be present
Use a single-dose unit without BAK	Lower literal risk	Other patents and device claims may apply
Use a different active ingredient	Outside this claim	Travoprost, latanoprost and tafluprost are different compounds
Change pH only	No effect on claim 1	pH matters mainly to claim 4
Change bottle or dropper	No effect on claim 1	Packaging limitation appears only in claim 3
Change bimatoprost concentration	Usually no effect on claim 1	Claim 1 has no express concentration limit
Add other excipients	Usually no effect	"Comprising" is open-ended

A sodium-chloride-free product would not necessarily be commercially clear. Other patents may cover bimatoprost compositions, preservative systems, low-concentration formulations, packaging, manufacturing processes or methods of treating glaucoma.

What is the FDA and Orange Book status of US 8,017,655?

Lumigan is associated with FDA NDA 021275. The original Lumigan product was approved as bimatoprost ophthalmic solution 0.03%. The lower-dose 0.01% formulation was later approved for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. [1,2]

US 8,017,655 was listed in connection with Lumigan in the FDA Orange Book patent framework. Orange Book listing does not establish validity or infringement. It does, however, make the patent relevant to an ANDA applicant that seeks approval for a product with the same active ingredient, dosage form, route and applicable labeling.

An ANDA applicant must address listed patents through a Paragraph I, II, III or IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed. The NDA holder can sue within the statutory period, triggering a potential 30-month approval stay under the Hatch-Waxman Act. [3]

Orange Book status is product-specific and can change as patents are delisted, expire or become irrelevant to a particular strength or formulation. The patent's relevance must therefore be assessed against the exact reference-listed drug, strength, dosage form and proposed generic formulation.

When does US Patent 8,017,655 lose exclusivity?

The statutory term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. A reliable commercial analysis should distinguish among:

The nominal patent term;
Any USPTO patent-term adjustment;
Any patent-term extension;
Orange Book listed expiration;
Regulatory exclusivity;
Pediatric exclusivity; and
Litigation-based approval delay.

Public patent records identify US 8,017,655 as an Allergan-related bimatoprost formulation patent with a projected expiration in the mid-2020s. The patent was granted on August 30, 2011. [4] The precise operative expiration date should be taken from the USPTO patent-term calculation and the current Orange Book listing rather than inferred solely from the grant date.

The patent does not create a separate period of FDA exclusivity. Its commercial effect is patent-based. FDA approval of a generic may proceed after the relevant patent barriers expire, are removed, are successfully challenged, or are addressed through a settlement allowing an earlier launch.

Exclusivity timeline

Event	Date or period	Relevance
Bimatoprost development and Lumigan approval	2001	Established the reference product
Lumigan 0.01% approval	2010	Expanded the commercial formulation relevant to later patent disputes
US 8,017,655 grant	August 30, 2011	Created the issued claim set
Patent term	20 years from relevant filing, subject to adjustment	Determines ordinary patent expiration
Generic entry	After patent and regulatory barriers	May occur earlier under settlement

Which companies challenged Lumigan and bimatoprost patent rights?

Generic drug companies have pursued bimatoprost ophthalmic products through the ANDA pathway. Publicly reported patent disputes have involved Allergan and generic applicants, including Sandoz and other applicants seeking approval for bimatoprost ophthalmic solutions.

The central litigation pattern is predictable under Hatch-Waxman:

A generic applicant files an ANDA.
The applicant submits a Paragraph IV certification against one or more Lumigan patents.
The NDA holder files a patent-infringement action.
FDA approval may be stayed for up to 30 months, subject to statutory exceptions.
The dispute resolves through trial, appeal, settlement or abandonment of the challenged product strategy.

A Paragraph IV filing against US 8,017,655 would likely focus on claim construction, obviousness, written description, enablement, anticipation, infringement and the relationship between the claimed excipient combination and the prior art. A generic applicant may also argue that its proposed formulation does not contain sodium chloride as a tonicity agent or does not contain benzalkonium chloride.

What patent litigation affects US 8,017,655?

The most important known litigation context is Allergan's enforcement of Lumigan-related patents against generic applicants. Federal Circuit and district court proceedings involving Lumigan and bimatoprost formulations have addressed the enforceability and validity of Allergan's patent estate, including disputes over obviousness and formulation technology. [5]

The litigation risk cannot be measured from claim language alone. A complete freedom-to-operate analysis must separate:

Infringement of claim 1;
Infringement of the narrower formulation claims;
Infringement of the method-of-use claims;
Validity after prior-art review;
Enforceability based on prosecution conduct;
Patent-term status;
Settlement restrictions; and
Other patents listed for Lumigan.

The existence of prior litigation does not automatically resolve the legal status of every claim. A judgment may address only a specific defendant, ANDA formulation, patent claim, prior-art record and procedural posture.

What other patents protect bimatoprost and Lumigan?

US 8,017,655 is one component of a broader bimatoprost estate. The relevant patent families generally fall into the following groups:

Active pharmaceutical ingredient patents

Earlier patents protected bimatoprost and related prostamide compounds. Those patents were the principal barriers to early generic competition but generally expired before the later formulation patents.

Formulation patents

Formulation patents cover combinations involving:

Bimatoprost concentration;
Benzalkonium chloride;
Sodium chloride or other tonicity agents;
Buffer systems;
pH;
Reduced-dose formulations;
Preservative levels;
Chemical stability; and
Ocular tolerability.

US 8,017,655 belongs primarily in this category.

Method-of-use patents

Method claims may cover reducing intraocular pressure, treating glaucoma, treating ocular hypertension, or using particular bimatoprost concentrations. Method-of-use patents can be relevant even when a generic applicant uses a section viii label carve-out for patented indications.

A carve-out does not eliminate composition-patent risk. If the generic formulation itself falls within an unexpired composition claim, removing a patented indication from the label will not avoid infringement of that composition claim.

Packaging and delivery patents

Dropper-specific claims, bottle systems and multidose preservative technologies may create separate infringement risks. Claim 3 of US 8,017,655 is limited to a composition packaged in a dropper, but the claim does not appear to cover every aspect of the dropper device.

Manufacturing patents

Manufacturing and purification patents may cover preparation of bimatoprost, control of impurities, crystallization, sterile filling and finished-product stability. These patents can create supply-chain barriers even when the finished formulation is outside US 8,017,655.

How strong is the patent estate for US 8,017,655?

The strength of the patent should be assessed claim by claim.

Factor	Assessment
Claim breadth	Claim 1 is broad because it lacks concentration and pH limitations
Technical specificity	The required BAK and sodium-chloride combination narrows the claim
Literal infringement clarity	High where the generic label and formulation disclose all three required ingredients
Design-around potential	Meaningful through preservative-free or sodium-chloride-free systems
Method-claim value	Lower where generic labeling omits patented indications
Prior-art exposure	Potentially material because ophthalmic bimatoprost formulations and excipients were known
Commercial relevance	High for preserved bimatoprost solutions matching Lumigan-type formulations
Estate dependency	High because other formulation and use patents may control launch timing

The strongest enforcement position is against a generic solution that reproduces the Lumigan formulation architecture: bimatoprost, benzalkonium chloride and sodium chloride in an ophthalmic composition. The weakest claims for launch control are likely claims 5 and 6 if the applicant can lawfully use a section viii label carve-out and no composition patent is infringed.

What generic launch scenarios exist for bimatoprost?

Scenario 1: Formulation matches claim 1

A generic applicant files a Paragraph IV certification and launches after litigation, settlement or patent expiry. This is the highest direct infringement-risk scenario.

Scenario 2: Sodium-chloride-free formulation

The applicant uses another tonicity agent and excludes sodium chloride. This may reduce risk under claim 1, but the formulation must be tested against other listed and unlisted patents.

Scenario 3: Preservative-free formulation

A unit-dose or preservative-free multidose product may avoid the benzalkonium-chloride limitation. Device and packaging patents may become more important.

Scenario 4: Section viii labeling

The applicant removes glaucoma or ocular-hypertension indications covered by method claims. This strategy does not avoid a composition claim.

Scenario 5: Settlement-based entry

The applicant accepts a delayed entry date, license terms, manufacturing restrictions or other settlement provisions. The commercial entry date then depends on the agreement and any FTC or court review.

How does bimatoprost compare with competing glaucoma drugs?

Bimatoprost competes primarily with latanoprost, travoprost and tafluprost, all prostaglandin-related intraocular-pressure-lowering products.

Product	Active ingredient	Typical patent issue	Formulation distinction
Lumigan	Bimatoprost	Bimatoprost formulation and use patents	Often preserved with BAK
Xalatan	Latanoprost	Compound, formulation and use patents	Different prostaglandin analog
Travatan Z	Travoprost	Formulation and preservative-system patents	SofZia preservative system
Zioptan	Tafluprost	Compound and formulation patents	Preservative-free unit-dose format

The active ingredients are chemically distinct. A competitor using latanoprost or travoprost does not infringe claim 1 merely because the products lower intraocular pressure. The relevant competitive risk is commercial substitution, not direct infringement of this patent.

What geographic coverage does US 8,017,655 provide?

US 8,017,655 provides rights in the United States only. It does not directly control:

European Union markets;
Canada;
Japan;
China;
India;
Latin America; or
Other jurisdictions.

Foreign counterparts may have different claim scope, prosecution histories, expiration dates and validity outcomes. A US Paragraph IV strategy does not determine the European or Canadian litigation position. International launch planning requires a separate family and national-phase review.

What are the principal IP barriers to a generic bimatoprost launch?

The major barriers are:

Unexpired composition patents covering bimatoprost with BAK and sodium chloride.
Other Orange Book-listed Lumigan patents.
Method-of-use patents that restrict labeling.
Formulation patents covering low-dose or preservative systems.
Manufacturing and sterile-filling patents.
Patent-term adjustment or pediatric exclusivity.
Hatch-Waxman litigation and a possible 30-month stay.
Commercial supply and device constraints.
Settlement restrictions affecting launch timing.
State-law or private-contract issues involving authorized generics and licensing.

The highest-value diligence item is a formulation-to-claim comparison based on the proposed generic's actual qualitative and quantitative composition. Label comparison alone is insufficient where the claim turns on whether sodium chloride functions as a tonicity agent.

Key Takeaways

US 8,017,655 is a bimatoprost formulation patent associated with the Lumigan product family.
Claim 1 requires bimatoprost, benzalkonium chloride and sodium chloride as a tonicity agent.
Claim 1 does not expressly require an ophthalmic route, dropper, pH range, concentration or glaucoma indication.
The claim's "comprising" language may capture formulations containing additional excipients.
A sodium-chloride-free or benzalkonium-chloride-free formulation is the clearest design-around direction, subject to other patents.
Claims 5 and 6 are method-of-use claims and may be addressed through a section viii labeling strategy, but that strategy does not avoid composition claims.
Lumigan-related generic entry has involved Paragraph IV litigation and broader Allergan bimatoprost patent enforcement.
The patent is US-only and must be analyzed separately from foreign counterparts.
The operative expiration date should be confirmed through the current USPTO patent-term record and FDA Orange Book listing.
The commercial risk depends on the full Lumigan patent estate, not US 8,017,655 alone.

FAQs About US Patent 8,017,655 and Bimatoprost

Does US 8,017,655 cover bimatoprost as a molecule?

No. The patent claims a pharmaceutical composition containing bimatoprost, benzalkonium chloride and sodium chloride. It is not a standalone compound claim to bimatoprost.

Can a generic use glycerin instead of sodium chloride?

Potentially. Replacing sodium chloride with glycerin may avoid literal infringement of claim 1 if the product contains no sodium chloride. Other patents and the doctrine of equivalents must still be evaluated.

Does changing the bimatoprost concentration avoid claim 1?

Not necessarily. The supplied claim does not specify a concentration. A concentration change alone may leave the product within claim 1.

Can a generic omit the glaucoma indication and avoid all patent risk?

No. Omitting a patented indication may address method-of-use claims, but it does not eliminate liability under a composition claim covering the formulation itself.

Does the patent cover preservative-free bimatoprost?

Claim 1 requires benzalkonium chloride. A genuinely preservative-free product would not literally satisfy that limitation, although other bimatoprost formulation, device or manufacturing patents may apply.

References

U.S. Food and Drug Administration. (2024). Lumigan (bimatoprost ophthalmic solution) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. FDA.
United States Patent and Trademark Office. (2011). U.S. Patent No. 8,017,655: Pharmaceutical composition. USPTO.
Allergan, Inc. v. Sandoz, Inc., 726 F.3d 1286 (Fed. Cir. 2013).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0660716	⤷ Start Trial	CA 2002 00020	Denmark	⤷ Start Trial
European Patent Office	0660716	⤷ Start Trial	SPC/GB02/035	United Kingdom	⤷ Start Trial
European Patent Office	0660716	⤷ Start Trial	90957	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,017,655